Portal de Periódicos da CAPES

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization

1997; Elsevier BV; Volume: 64; Issue: 6 Linguagem: Inglês

10.1006/exer.1997.0292

1096-0007

B. M. Kenyon, Fiona Browne, Robert J. D’Amato,

Angiogenesis and VEGF in Cancer

Thalidomide, when administered orally, is an inhibitor of angiogenesis in the basic fibroblast growth factor (bFGF)-induced rabbit cornea micropocket assay. We now show in the mouse that thalidomide given intraperitoneally but not orally significantly inhibits bFGF-induced and vascular endothelial growth factor (VEGF)-induced corneal neovascularization. We further demonstrate that this inhibition is independent from thalidomide's ability to suppress tumor necrosis factor-alpha (TNF-alpha) production. Experiments examining thalidomide's enantiomers reveal-that the S(-)-enantiomer has the strongest antiangiogenic activity in VEGF-induced and bFGF-induced corneal neovascularization. Structure activity studies suggest that thalidomide's anti-angiogenic activity is related to the open ring metabolites resulting from hydrolysis. Together these data support a correlation between thalidomide's antiangiogenic and teratogenic activities.